In 2025 a new treatment option gained U.S. Food and Drug Administration (FDA) approval for people with moderate to severe rheumatoid arthritis (RA) who have not responded to other treatments. “The approval of vagus nerve stimulation for RA represents a disruptive advance in our therapeutic paradigm,” says Cleveland Clinic rheumatologist Leonard Calabrese, D.O. “It shifts us from exclusive reliance on disease modifying anti-rheumatic drugs (DMARDs) for immunosuppression toward targeted nerve modulation using an implanted device.”
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe to Arthritis Advisor
Get the next year of Arthritis Advisor for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 36%. It's like getting 4 months FREE!
